Physician profile
Amanda Stephens
NPI 1194148767
$8,064.76
in general payments reported to CMS, 2019-2025
53 companies · $1,345 in 2025
The $1,345 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,717 · 2022: $1,560 · 2023: $1,855 · 2024: $1,587 · 2025: $1,345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,763 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,762.91 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,259.28 | 2021-2025 | |
| Amgen INC. | $1,170.28 | 2021-2025 | Evenity, Prolia, Otezla |
| Novo Nordisk INC | $836.46 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $613.16 | 2021-2024 | Mounjaro, Jardiance, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $490.21 | 2021-2025 | Jardiance |
| Pfizer INC. | $324.41 | 2021-2025 | |
| Glaxosmithkline, LLC. | $319.80 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $292.50 | 2021-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $242.07 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Amarin Pharma, INC. | $174.80 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $171.94 | 2022-2025 | |
| Biohaven Pharmaceuticals, INC. | $165.01 | 2021 | |
| Idorsia Pharmaceuticals US INC | $159.86 | 2022-2024 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $159.80 | 2021-2023 | Trintellix |
| Dexcom, INC. | $127.42 | 2022-2025 | Dexcom G6 Transmitter |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Stephens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.